nach oben

Molecular Diagnosis & Therapy

Erschienen in:

01.05.2006 | Original Research Article

Pharmacogenetic Screening for Polymorphisms in Drug-Metabolizing Enzymes and Drug Transporters in a Dutch Population

verfasst von: T. M. Bosch, PhD PharmD, V. D. Doodeman, P. H. M. Smits, I Meijerman, J. H. M. Schellens, J. H. Beijnen

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Abstract

Background: A possible explanation for the wide interindividual variability in toxicity and efficacy of drug therapy is variation in genes encoding drug-metabolizing enzymes and drug transporters. The allelic frequency of these genetic variants, linkage disequilibrium (LD), and haplotype of these polymorphisms are important parameters in determining the genetic differences between patients. The aim of this study was to explore the frequencies of polymorphisms in drug-metabolizing enzymes (CYP1A1, CYP2C9, CYP2C19, CYP3A4, CYP2D6, CYP3A5, DPYD, UGT1A1, GSTM1, GSTP1, GSTT1) and drug transporters (ABCB1[MDR1] and ABCC2[MRP2]), and to investigate the LD and perform haplotype analysis of these polymorphisms in a Dutch population.

Methods: Blood samples were obtained from 100 healthy volunteers and genomic DNA was isolated and amplified by PCR. The amplification products were sequenced and analyzed for the presence of polymorphisms by sequence alignment.

Results: In the study population, we identified 13 new single nucleotide polymorphisms (SNPs) in Caucasians and three new SNPs in non-Caucasians, in addition to previously recognized SNPs. Three of the new SNPs were found within exons, of which two resulted in amino acid changes (A428T in CYP2C9 resulting in the amino acid substitution D143V; and C4461T in ABCC2 in a non-Caucasian producing the amino acid change T1476M). Several LDs and haplotypes were found in the Caucasian individuals.

Conclusion: In this Dutch population, the frequencies of 16 new SNPs and those of previously recognized SNPs were determined in genes coding for drug-metabolizing enzymes and drug transporters. Several LDs and haplotypes were also inferred. These data are important for further research to help explain the interindividual pharmacokinetic and pharmacodynamic variability in response to drug therapy.

Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 2003 Feb; 17(1): 27–41PubMedCrossRef

Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2001 Feb; 2(1): 51–64PubMedCrossRef

Bartsch H, Nair U, Risch A, et al. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 2000 Jan; 9(1): 3–28PubMed

Dunning AM, Healey CS, Pharoah PD, et al. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999 Oct; 8(10): 843–54PubMed

Human cytochrome P450 (CYP) allele nomenclature committee [online]. Available from URL: http://www.imm.ki.se/CYPalleles/ [Accessed 2006 May 8]

ABC-transporter genes [online]. Available from URL: http://www.gene.ucl.ac.uk/nomenclature/genefamily/abc.html [Accessed 2006 May 8]

Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001 Dec; 299(3): 825–31PubMed

Eiselt R, Domanski TL, Zibat A, et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 2001 Jul; 11(5): 447–58PubMedCrossRef

vonAhsen N, Richter M, Grupp C, et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001 Jun; 47(6): 1048–52

10.

Anglicheau D, Thervet E, Etienne I, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004 May; 75(5): 422–33PubMedCrossRef

11.

Plasschaert SL, Groninger E, Boezen M, et al. Influence of functional polymorph-isms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther 2004 Sep; 76(3): 220–9PubMedCrossRef

12.

The European agency for the evaluation of medicinal products. Note for guidance on good clinical practice [online]. Available from URL: http://www.emea.eu.int/pdfs/human/ich/013595en.pdf [Accessed 2006 May 24]

13.

Boom R, Sol CJ, Salimans MM, et al. Rapid and simple method for purification of nucleic acids.J Clin Microbiol 1990 Mar; 28(3): 495–503PubMed

14.

Cascorbi I, Brockmoller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996 Nov 1; 56(21): 4965–9PubMed

15.

Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996 Aug; 6(4): 341–9PubMedCrossRef

16.

Goldstein JA, Blaisdell J. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol 1996; 272: 210–8PubMedCrossRef

17.

Sata F, Sapone A, Elizondo G, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000 Jan; 67(1): 48–56PubMedCrossRef

18.

vanSchaik RH, van der Heiden I, van den Anker JN, et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002 Oct; 48(10): 1668–71PubMed

19.

Schur BC, Bjerke J, Nuwayhid N, et al. Genotyping of cytochrome P450 2D6*3 and *4 mutations using conventional PCR. Clin Chim Acta 2001 Jun; 308(1-2): 25–31PubMedCrossRef

20.

vanKuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000 Dec; 6(12): 4705–12PubMed

21.

Huang CS, Luo GA, Huang ML, et al. Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese. Pharmacogenetics 2000 Aug; 10(6): 539–44PubMedCrossRef

22.

Sreelekha TT, Ramadas K, Pandey M, et al. Genetic polymorphism of CYP1A1, GSTM1 and GSTT1 genes in Indian oral cancer. Oral Oncol 2001 Oct; 37(7): 593–8PubMedCrossRef

23.

Jeronimo C, Varzim G, Henrique R, et al. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2002 May; 11(5): 445–50PubMed

24.

Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003; 43: 285–307PubMedCrossRef

25.

Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000 Mar 28; 97(7): 3473–8PubMedCrossRef

26.

Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001 Aug; 70(2): 189–99PubMedCrossRef

27.

Ito S, Ieiri I, Tanabe M, et al. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001 Mar; 11(2): 175–84PubMedCrossRef

28.

Scordo MG, Aklillu E, Yasar U, et al. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001 Oct; 52(4): 447–50PubMedCrossRef

29.

Scordo MG, Caputi AP, D’Arrigo C, et al. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004 Aug; 50(2): 195–200PubMedCrossRef

30.

Yasar U, Eliasson E, Dahl ML, et al. Validation of methods for CYP2C9 genotyp-ing: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999 Jan 27; 254(3): 628–31PubMedCrossRef

31.

Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002 Apr; 12(3): 251–63PubMedCrossRef

32.

Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003 Aug; 59(4): 303–12PubMedCrossRef

33.

Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997 Feb; 7(1): 59–64PubMedCrossRef

34.

Hoskins JM, Shenfield GM, Gross AS. Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population. Br J Clin Pharmacol 1998 Nov; 46(5): 499–504PubMedCrossRef

35.

Xie HG, Stein CM, Kim RB, et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999 Oct; 9(5): 539–49PubMedCrossRef

36.

Ball SE, Scatina J, Kao J, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 1999 Sep; 66(3): 288–94PubMedCrossRef

37.

Hamzeiy H, Vahdati-Mashhadian N, Edwards HJ, et al. Mutation analysis of the human CYP3A4 gene 5′ regulatory region: population screening using non-radioactive SSCP. Mutat Res2002 Mar 20; 500(1-2): 103–10PubMedCrossRef

38.

vanSchaik RH, deWildt SN, van Iperen NM, et al. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin Chem 2000 Nov; 46(11): 1834–6PubMed

39.

Walker AH, Jaffe JM, Gunasegaram S, et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum Mutat 1998; 12(4): 289PubMed

40.

Garcia-Martin E, Martinez C, Pizarro RM, et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 2002 Mar; 71(3): 196–204PubMedCrossRef

41.

Lee SJ, Usmani KA, Chanas B, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003 Aug; 13(8): 461–72PubMedCrossRef

42.

Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004 Apr; 5(3): 243–72PubMedCrossRef

43.

vanKuilenburg AB, Muller EW, Haasjes J, et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 2001 May; 7(5): 1149–53PubMed

44.

Lampe JW, Bigler J, Horner NK, et al. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 1999 Jun; 9(3): 341–9PubMedCrossRef

45.

Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998 Jul 7; 95(14): 8170–4PubMedCrossRef

46.

Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1 A1 promoter polymorphism. Clin Pharmacol Ther 1999 May; 65(5): 576–82PubMedCrossRef

47.

Fertrin KY, Goncalves MS, Saad ST, et al. Frequencies of UDP-glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil. Am J Med Genet 2002 Mar 1; 108(2): 117–9PubMedCrossRef

48.

Viezzer C, Norppa H, Clonfero E, et al. Influence of GSTM1, GSTT1, GSTP1, and EPHX gene polymorphisms on DNA adduct level and HPRT mutant frequency in coke-oven workers. Mutat Res 1999 Dec 17; 431(2): 259–69PubMedCrossRef

49.

Krajinovic M, Labuda D, Richer C, et al. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999 Mar 1; 93(5): 1496–501PubMed

50.

Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001 Dec; 10(12): 1239–48PubMed

51.

Ballerini S, Bellincampi L, Bernardini S, et al. Analysis of GSTP1-1 polymorphism using real-time polymerase chain reaction. Clin Chim Acta 2003 Mar; 329(1-2): 127–32PubMedCrossRef

52.

Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003 Aug; 13(8): 481–94PubMedCrossRef

53.

Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001 Mar; 69(3): 169–74PubMedCrossRef

54.

Furuno T, Landi MT, Ceroni M, et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson’s disease. Pharmacogenetics 2002 Oct; 12(7): 529–34PubMedCrossRef

55.

Gerloff T, Schaefer M, Johne A, et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 2002 Dec; 54(6): 610–6PubMedCrossRef

56.

Schaeffeler E, Eichelbaum M, Brinkmann U, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001 Aug 4; 358(9279): 383–4PubMedCrossRef

57.

Drozdzik M, Bialecka M, Mysliwiec K, et al. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson’s disease. Pharmacogenetics 2003 May; 13(5): 259–63PubMedCrossRef

58.

Fukushima-Uesaka H, Saito Y, Watanabe H, et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 2004 Jan; 23(1): 100PubMedCrossRef

59.

Collie-Duguid ES, Etienne MC, Milano G, et al. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000 Apr; 10(3): 217–23PubMedCrossRef

60.

Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002 Mar; 8(3): 768–74PubMed

61.

vanKuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004 May; 40(7): 939–50PubMedCrossRef

62.

Marcuello E, Altes A, Menoyo A, et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004 Aug 16; 91(4): 678–82PubMed

63.

Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000 Dec 15; 60(24): 6921–6PubMed

64.

Hitzl M, Drescher S, van der Banti KH, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001 Jun; 11(4): 293–8PubMedCrossRef

65.

Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotype-related pharma-cokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001 Oct; 18(10): 1400–4PubMedCrossRef

66.

Saitoh A, Singh KK, Powell CA, et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 2005 Mar 4; 19(4): 371–80PubMedCrossRef

67.

Tang K, Ngoi SM, Gwee PC, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002 Aug; 12(6): 437–50PubMedCrossRef

68.

Tang K, Wong LP, Lee EJ, et al. Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum Mol Genet 2004 Apr 15; 13(8): 783–97PubMedCrossRef

69.

Sai K, Kaniwa N, Itoda M, et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 2003 Dec; 13(12): 741–57PubMedCrossRef

70.

Allabi AC, Horsmans Y, Issaoui B, et al. Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population. Eur J Clin Pharmacol 2005 Apr; 61(2): 97–102PubMedCrossRef

71.

Wada M, Toh S, Taniguchi K, et al. Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet 1998 Feb; 7(2): 203–7PubMedCrossRef

72.

Toh S, Wada M, Uchiumi T, et al. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet 1999 Mar; 64(3): 739–46PubMedCrossRef

73.

Itoda M, Saito Y, Soyama A, et al. Polymorphisms in the ABCC2 (cMOAT/ MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5′-untranslated region and Exon 28. Drug Metab Dispos 2002 Apr; 30(4): 363–4PubMedCrossRef

74.

Mor-Cohen R, Zivelin A, Rosenberg N, et al. Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J Biol Chem 2001 Oct 5; 276(40): 36923–30PubMedCrossRef

75.

Kuwano M, Toh S, Uchiumi T, et al. Multidrug resistance-associated protein subfamily transporters and drug resistance. Anticancer Drug Des 1999 Apr; 14(2): 123–31PubMed

76.

Materna V, Lage H. Homozygous mutation Arg768Trp in the ABC-transporter encoding gene MRP2/cMOAT/ABCC2 causes Dubin-Johnson syndrome in a Caucasian patient. J Hum Genet 2003; 48(9): 484–6PubMedCrossRef

77.

Hulot JS, Villard E, Maguy A, et al. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 2005 May; 15(5): 277–85PubMedCrossRef

Titel: Pharmacogenetic Screening for Polymorphisms in Drug-Metabolizing Enzymes and Drug Transporters in a Dutch Population
verfasst von: T. M. Bosch, PhD PharmD
V. D. Doodeman
P. H. M. Smits
I Meijerman
J. H. M. Schellens
J. H. Beijnen
Publikationsdatum: 01.05.2006
Verlag: Springer International Publishing
Erschienen in: Molecular Diagnosis & Therapy / Ausgabe 3/2006
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI: https://doi.org/10.1007/BF03256456

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Pharmacogenetic Screening for Polymorphisms in Drug-Metabolizing Enzymes and Drug Transporters in a Dutch Population

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2006

Diagnosis, Pathogenesis, and Treatment Prospects in Cystic Kidney Disease

The AmpliChip™ CYP450 Genotyping Test

Comparison of 12 Reference Genes for Normalization of Gene Expression Levels in Epstein-Barr Virus-Transformed Lymphoblastoid Cell Lines and Fibroblasts

Pharmacogenetic Issues in Thorough QT Trials

Hepatic Gene Expression Response to Acute Indomethacin Exposure

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin